AMRN
Amarin CorpAMRN
AMRN
About: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Employees: 275
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
281% more call options, than puts
Call options by funds: $392K | Put options by funds: $103K
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
3.62% less ownership
Funds ownership: 19.56% [Q2] → 15.94% (-3.62%) [Q3]
7% less funds holding
Funds holding: 169 [Q2] → 157 (-12) [Q3]
26% less capital invested
Capital invested by funds: $55.3M [Q2] → $41.1M (-$14.2M) [Q3]
41% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 29
43% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 44
Research analyst outlook
We haven’t received any recent analyst ratings for AMRN.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Amarin Receives National Reimbursement for VAZKEPA® in Italy
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients 1 -- -- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --
Neutral
GlobeNewsWire
1 week ago
Amarin Appoints Peter Fishman Chief Financial Officer
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company
Negative
Zacks Investment Research
1 month ago
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks You'll Regret Missing In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
Zacks Investment Research
1 month ago
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year.
Neutral
Seeking Alpha
1 month ago
Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co. Paul Choi - Goldman Sachs Group Inc. Operator Welcome to Amarin Corporation's Conference Call to discuss its Third Quarter 2024 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
Neutral
GlobeNewsWire
3 months ago
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Spain.
Neutral
GlobeNewsWire
4 months ago
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024.
Neutral
Zacks Investment Research
4 months ago
Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Neutral
Seeking Alpha
4 months ago
Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Mark Marmur – Vice President, Corporate Communications and Investor Relations Aaron Berg – President and Chief Executive Officer Tom Reilly – Chief Financial Officer Jonathan Provoost – Executive Vice President, Chief Legal and Compliance Officer Steven Ketchum – Executive Vice President, President-R&D, Chief Scientific Officer Conference Call Participants Carvey Leung – Cantor Jessica Fye – JPMorgan Paul Choi – Goldman Sachs Operator Welcome to Amarin Corporation's Conference Call to discuss its Second Quarter 2024 Business Update and Financial Results. I would now like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.
Charts implemented using Lightweight Charts™